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Allele-Skewed DNA Modification in the Brain:
Relevance to a Schizophrenia GWAS
Sarah A. Gagliano,1,3,8 Carolyn Ptak,1,8 Denise Y.F. Mak,1,2,8 Mehrdad Shamsi,1,2 Gabriel Oh,1
Joanne Knight,1,3,4,7 Paul C. Boutros,2,5,6,* and Arturas Petronis1,3,4,5,*
Numerous recent studies have suggested that phenotypic effects of DNA sequence variants can bemediated or modulated by their epige-
neticmarks, such as allele-skewedDNAmodification (ASM). Using Affymetrix SNPmicroarrays, we performed a comprehensive search of
ASM effects in human post-mortem brain and sperm samples (total n ¼ 256) from individuals with major psychosis and control indi-
viduals. Depending on the phenotypic category of the brain samples, 1.4%–7.5% of interrogated SNPs exhibited ASM effects. Next, we
investigated ASM in the context of genetic studies of schizophrenia and detected that brain ASM SNPs were significantly overrepresented
among sub-threshold SNPs from a schizophrenia genome-wide association study (GWAS). Brain ASM SNPs showed a much stronger
enrichment in a schizophrenia GWAS than in 17 large GWASs of non-psychiatric diseases and traits, arguing that ASM effects are at least
partially tissue specific. Studies of germline and control brain ASM SNPs supported a causal association between ASM and schizophrenia.
Finally, significantly higher proportions of ASM SNPs than of non-ASM SNPs were detected at loci exhibiting epigenetic signatures
of enhancers and promoters, and they were overrepresented within transcription factor binding regions and DNase I hypersensitive
sites. All of these findings collectively indicate that ASM SNPs should be prioritized in follow-up GWASs.Genome-wide association studies (GWASs) have become
the key approach to identifying DNA variants that influ-
ence complex traits. As a rule, even well-powered GWASs
detect only a small number of genome-wide-significant
SNPs (5 3 108 is the accepted p value significance
threshold in GWASs1), whereas thousands of SNPs fall
into the gray zone of sub-threshold p values. It has been
demonstrated that SNPs that do not reach GWAS signifi-
cance (even those with p values as high as 0.1) account
for a considerable proportion of predisposition to disease
and contribute to ‘‘missing’’ heritability.2 Separation of
biological signal from noise within this sub-threshold
zone requires hundreds of thousands of additional individ-
uals,3,4 but collecting these is expensive and might not
even be feasible for rare phenotypes. Genetic-epigenetic
interactions could provide new insights for prioritization
of sub-threshold GWAS SNPs. SNPs that exhibit allele-
skewed modification (ASM; ‘‘modification’’ is used to
denote various types of epigenetic cytosine marks in addi-
tion to methylation) are particularly interesting, because
differential modifications might provide a mechanism for
DNA polymorphisms to affect regulation of protein-coding
genes and non-coding regions.5,6 ASM refers to differential
DNA modification of alleles in the vicinity of the poly-
morphic DNA site. Systematic analysis of ASM SNPs in
GWASs has been proposed numerous times,5,6 but its
testing has been hampered by a lack of comprehensive
lists of tissue-specific ASM SNPs and poor overlap between
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6.0 microarrays).
To explore the relationshipbetweenGWAS sub-threshold
SNPs and ASM, we identified brain ASM SNPs from control
individuals and individuals affectedby schizophrenia (SCZ)
or bipolar disorder (BPD). Frozen prefrontal cortex (Brod-
mann area 10) tissues from post-mortem control subjects
(n ¼ 76), BPD individuals (n ¼ 67), and SCZ individuals
(n ¼ 65) were obtained from the Stanley Medical Research
Institute and the Harvard Brain Tissue Resource Center.
Theoverwhelmingmajorityof the individualswereof Euro-
pean origin: n¼ 74 in the control group, n¼ 65 in the BPD
group, andn¼ 64 in the SCZ group (as verified by principal-
component analysis). We also investigated sperm samples
from BPD individuals (n ¼ 24) and control individuals
(n ¼ 24). Germline samples were collected in accordance
with the ethical standards of the Centre for Addiction and
Mental Health (Toronto), and informed consent from
each donor was obtained. Germ cells were isolated from
semen according to the two-layer discontinuous-gradient-
separation protocol (ISolate, Irvine Scientific). DNA sam-
ples from brain tissues and sperm were extracted via the
standard phenol-chloroform method. Additional demo-
graphic data for all of the brain and sperm samples are sum-
marized in Table S1.
To make our analysis of ASM SNPs applicable to GWASs,
we used Affymetrix Genome-Wide Human SNP Array 6.0,
which is one of the most common GWAS platforms and
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Figure 1. Beeswarm Plots of Unmodified DNA Signal Intensity
by Genotype
Examples of (A) ASM SNP rs16835902 (C/G; chromosome 3) and
(B) non-ASM SNP rs39704 (C/T; chromosome 3). On the basis of
the sequences flanking the SNPs, the informative enzymes for
rs16835902 and rs39704 were HpaII and HpyCH4IV, respectively.Each of the 256 DNA samples from brain and sperm was
interrogated twice on this platform. First, we performed
regular SNP genotyping according to the manufacturer’s
instructions. Second, we investigated allelic differences
in DNA modification by enriching the unmodified DNA
fraction with restriction enzymes sensitive to DNA modifi-
cation.10 For each sample, 500 ng of genomic DNA was
separately digested with three restriction enzymes: HpaII,
HinP1I, and HpyCH4IV (New England Biolabs). The three
digests per sample were then pooled in equal amounts, and
adaptors were ligated onto the ends of DNA fragments. To
eliminate the fragments containing modified cytosines
between the restriction enzyme targets, we additionally
digested ligation products with McrBC (New England Bio-
labs). Samples were then amplified by PCR using primers
complementary to the adaptor sequences, fragmented
with DNaseI (EpiCentre), labeled (GeneChip DNA labeling
reagent, Affymetrix), and hybridized to Affymetrix SNP
Array 6.0. Because DNA fragments longer than 2 kb cannot
be efficiently amplified under standard PCR conditions,
the interrogated ASM effects were limited to <2 kb regions
surrounding a SNP. We used R (v.2.12.1)11 and the crlmm
R package (v.1.8.11) to background correct, normalize,
and summarize (via RMA) the SNP probes and to make ge-
notype calls. Datasets were normalized separately, as were
genotyping and DNA-modification arrays. For each SNP,
we obtained a genotype call and a DNA-modification level
for each allele.
Depending on the cohort being examined, we removed
260,900–365,830 (28.8%–40.4%) SNPs that failed our qual-
ity-control tests. Such SNPs were missing annotation infor-
mation,werenot foundonautosomesor sex chromosomes,
diverged from Hardy-Weinberg equilibrium (HWE), or ex-
hibited a low minor allele frequency or low genotype-call
confidence. There was no particular sample with unusually
low genotype-call confidence rates; therefore, all samplesThe Amwere included in the analysis. We used a threshold of p <
1010 to filter SNPs that failed HWE, and the vast majority
of SNPs were in even stronger agreement with HWE: 97%
of SNPswithp>1010 also exhibitedp>107. Batch effects
were examined via principal-component analysis, and no
outliers were found upon visual inspection of the first two
principal components.
To identify ASM SNPs, we investigated the relationship
betweenmodification and genotype. To optimize detection
of ASM SNPs, we performed a large-scale simulation study
to test five statistical models: Pearson’s correlation, Spear-
man’s rank-order correlation, mutual information, piece-
wise linear regression (PWL), and ANOVA. To compare
these statistical methods, we generated a simulated dataset
of 100 paired samples with 1,000,000 SNPs representative
of our samples according to a probability distribution in
which the genotype values and the mean 5 SD of
the DNA-modification levels represented ternary and
continuous variables, respectively. We added a row-wise
dependency for 100,000 SNPs by adding a random signal-
intensity offset uniformly sampled from the set {0.25, 0.5,
0.75}. We varied an adjusted p value threshold and
compared the number of dependencies found (Figure S1).
We used receiver-operation-characteristic (ROC) curves
(Figure S2) to visualize the overall performanceof eachmea-
sure across all false-discovery-rate (FDR)-adjusted p value
thresholds.12ANOVAandPWLwere the top twoperformers
in terms of sensitivity and specificity and showed nearly
identical ROC curves with a true-positive rate ~50% when
the false-positive rate was ~10%. We chose PWL, which is
the ideal choice for large-scale data when multiple CPU
cores are used. Furthermore, PWL is a two-step linear-regres-
sionmodel that provides a pattern of dependency between
the genotypes AA to AB (slope 1) and AB to BB (slope 2).
Statistically significant allelic DNA-modification differ-
ences were identified as ASM SNPs if they had at least one
non-zero slope (i.e., either AA versus AB or AB versus BB)
with q < 0.01.
We classified SNPs with FDR < 0.01 as ASM SNPs and
removed SNPs in linkage disequilibrium (LD) with one
another (r2 > 0.25). We generated four lists of ASM SNPs:
1,374 ASM SNPs were detected in control brains (1.31%
of all SNPs investigated), 2,921 were detected in SCZ brains
(2.79%), 1,313 were detected in BPD brains (1.25%), and
7,744 were detected across all brain samples (7.40%).
Examples of an ASM SNP and a non-ASM SNP are shown
in Figure 1. All pairwise overlaps among the four lists of
ASM SNPs were significantly higher than expected by
chance alone (p < 2.2 3 1016, hypergeometric test;
Figure 2).
Our primary goal was to evaluate whether brain ASM
SNPs could help prioritize sub-threshold GWAS SNPs
in psychiatric diseases. To test this hypothesis, we split
the SCZ GWAS3 (henceforth referred to as the 81K SCZ
GWAS; n ¼ 81,080 SCZ case and control individuals)
SNPs into ten bins by p value (p % 0.1, 0.1 < p % 0.2,
0.2 < p% 0.3,. 0.9 < p% 1). Using the hypergeometricerican Journal of Human Genetics 98, 956–962, May 5, 2016 957
Figure 3. Distribution of ASM SNPs in SCZ GWAS p Value Bins
(A) ASM SNPs detected in the brains of control, SCZ, and BPD in-
dividuals were overrepresented in the SCZ GWAS sub-threshold
p % 0.1 SNP group. SCZ GWAS p value bins are plotted on the
x axis, and log10 p values are on the y axis.
(B) Further division of the ASM SNPs in the GWAS p % 0.05 bin
revealed the highest density of ASM SNPs in the p % 0.01 sub-
threshold bin.
Figure 2. Overlap of Identified ASM SNPs among the Four Brain
Cohorts
Abbreviations are as follows: all brain, ASM SNPs identified across
all brains; SCZ, ASM SNPs identified in the brains of individuals
with schizophrenia; control, ASM SNPs identified in the control
brains; and BPD, ASM SNPs identified in the brains of individuals
with bipolar disorder.test, we assessed enrichment of ASM SNPs in GWAS p value
bins in relation to a background of interrogated SNPs lack-
ing ASM effects (non-ASM SNPs). We pruned both the
GWAS list and the lists of ASM SNPs to ensure that our ob-
servations were not confounded by correlated SNPs. Prun-
ing, which was based on an r2 of 0.25 and a window size
of 500 kb with a shift of five SNPs between windows, was
implemented in PLINK.13 It was conducted with the LD
structure from the HapMap Project’s CEU (Utah residents
with ancestry from northern and western Europe from
the CEPH collection) samples (phase 2, release 23)14 to
reflect the lists of European-derived ASM SNPs. (HapMap
data files were downloaded from the PLINK website.)
All four lists of brain ASM SNPs showed significant
enrichment in the GWAS p % 0.1 bin, but not in any of
the other nine bins (Figure 3A; Table S2). The strongest evi-
dence supporting enrichment ofASMSNPswasdetected for
the group of all brain ASM SNPs (odds ratio [OR] ¼ 1.31,
95% confidence interval [CI] ¼ 1.23–1.38; p ¼ 2.03 3
1019, hypergeometric test; Figure 3A). No enrichment
was observed in randomsets of SNPs (Table S2). This pattern
heldwhen the p% 0.1 binwas further divided into five sub-
bins between p values 0 and 0.05, where the strongest
enrichment of ASM SNPs in the SCZ GWAS SNPs with
p % 0.01 was detected (Figure 3B; Table S3). For example,
the number of observed SCZ ASM SNPs in the GWAS
p% 0.01 sub-bin was 76% larger than expected by chance
(181 versus 103; OR ¼ 1.55, 95% CI ¼ 1.2–2.1; p ¼ 2.85 3
1013, hypergeometric test). By contrast, the number of
ASM SNPs with the GWAS 0.04 < p % 0.05 sub-bin was
indistinguishable from that expected by chance alone
(Table S3).
The same trend applied to the sub-bins lower than p %
0.01: the more significant the p value sub-bin, the higher
the proportion of ASM SNPs. For example, SCZ ASM
SNPs in the SCZ GWAS SNPs with p < 107 exhibited an958 The American Journal of Human Genetics 98, 956–962, May 5, 2OR of 7.3, whereas the OR was 1.4 for 0.001 % p < 0.01
(Figure S3).
To demonstrate that analysis of ASM SNPs can identify
sub-threshold GWAS SNPs more likely to be disease associ-
ated, we analyzed a 52,000-individual SCZ GWAS (here-
after referred to as the 52K SCZ GWAS),15 which was
a subset of the 81K SCZ GWAS. We categorized sub-
threshold (5 3 108 < p < 0.1) GWAS SNPs in the 52K
SCZ GWAS as either ASM SNPs or non-ASM SNPs and
tested how these two categories performed in the 81K
SCZ GWAS. In the quantile-quantile plot of the p values
in the 81K SCZ GWAS, the ASM SNPs showed a steeper
slope than did the non-ASM SNPs (Figure 4 plots observed
p values against expected p values). This demonstrates the
potential of ASM SNPs to prioritize GWAS candidates.
Next, we assessed whether brain ASM SNPs can also be
useful for candidate prioritization in other GWASs. We
tested the same four lists of brainASMSNPs in 17 additional
large GWASs (>15,000 individuals, range ¼ 15,000–
170,000,mean¼ 89,700, SD545,700; Table S4) conducted
from 2010 onward for non-psychiatric diseases and normal
traits. Generally, if the same study conducted more than
oneGWAS on correlated traits, we selected the largest. After
Bonferroni correction for multiple testing (720 tests were
performed in total: four lists ofASMSNPs, tenGWASpvalue
bins, and 18 GWASs), only three GWASs (in addition to016
Figure 4. Quantile-Quantile Plot Shows ASM SNPs and Non-
ASM SNPs with a p% 0.1 in the 52K SCZ GWAS
The observed quantiles were derived from the 81K SCZ GWAS
p values for the respective SNPs, whereas the expected quantiles
were from a continuous uniform distribution of p values. The
steeper slope of the ASM SNPs indicates that these SNPs had lower
p values in the 81K SCZ GWAS (where both the sample size and
power were greater) than did the non-ASM SNPs. The plotted
ASM SNPs are those from all brains in the p % 0.1 bin of the
52K SCZ GWAS (n ¼ 1,376), and the plotted non-ASM-SNPs are
those from the 52K SCZ GWAS p % 0.1 bin (n ¼ 163,592 from
the total 1,252,902 SNPs tested in the 52K SCZ GWAS).SCZ) demonstrated enrichment of p < 0.01 for at least one
of the four lists of ASM SNPs: high-density lipoprotein,
platelet count, and coronary heart disease (Figures 5 and
6; Figure S4; Table S4; Table S5). SCZ and cardiovascular
traits exhibited strong association,16 which could partially
be determined by common genetic and epigenetic factors.Figure 5. Distribution of log10 p Values for Four Lists of Brain AS
The p values were corrected for multiple testing. Only GWAS SNP p
thousands (K) is shown above each row of ASM SNP p values.
The AmAs in all epigenetic studies, the association between
epigenetic factors and phenotypes raises a question about
the direction of effect. Brain ASM SNPs might predispose
to SCZ or might be induced by pathological processes in
the brain, by treatment, or by other disease-associated
factors. Two lines of evidence supported (but did not
prove) a causal relationship between ASM and SCZ. First,
ASM SNPs detected in psychiatric-disease-free (control)
brains were enriched in the SCZ GWAS p % 0.1 bin
(Figure 3A; Table S2), indicating that ASM effects are pre-
sent before disease onset. Second, we analyzed ASM SNPs
in sperm samples from BPD males (n ¼ 24) and age-
matched control individuals (n ¼ 24) as outlined above.
There was significant overlap between the lists of sperm
ASM SNPs and the list of all brain ASM SNPs. Forty-one
(56%) of the BPD-sperm ASM SNPs were also in the list
of all brain ASM SNPs, and 134 (49%) of the control-
sperm ASM SNPs were also in the list of all brain ASM
SNPs (p< 2.23 1016 for both comparisons, hypergeomet-
ric test). Enrichments in the SCZ GWAS p % 0.1 bin were
detected for ASM SNPs from both the control-sperm list
(51 versus 37; OR ¼ 1.49, 95% CI ¼ 1.08–2.02; p ¼ 6.9 3
103, hypergeometric test) and the BPD-sperm list (20
versus 10; OR ¼ 2.38, 95% CI ¼ 1.36–4.01; p ¼ 7.7 3
104, hypergeometric test), but not in any other bin
(Table S2). This finding, although not sufficiently robust
to withstand multiple-testing correction, suggests a causal
relationship between ASM SNPs and SCZ.
To further elucidate the roles of ASM SNPs in disease, we
explored functional features of the genomic regions in
which they are located. Splice sites and nonsynonymous
SNPs were taken from the UCSC Genome Browser.17
Splice-site boundaries were defined as a window of 5 bp
upstream and 5 bp downstream of a splice site. Nonsynony-
mous variants (coding SNPs that fall into one of the
following categories: nonsense, missense, stop loss, frame-
shift, or in-frame indel) were defined as a single base pair.M SNPs Interrogated in 18 Large GWASs
% 0.1 bins are presented here. The sample size of each GWAS in
erican Journal of Human Genetics 98, 956–962, May 5, 2016 959
Figure 6. ORs for the Enrichment of ASM SNPs in the p % 0.1 Bin for Various GWASs
The colored bars are the lists of those ASM SNPs that were significantly enriched in the GWAS p% 0.1 bin after correction for multiple
testing (p < 0.01).cis-eQTLs were defined as single base pairs from the Geno-
type-Tissue Expression Project (GTEx)18–21 and theUKBrain
Expression Consortium.22 DNase hypersensitive clusters,
available through the ENCODE project,23 were created
from all available cell types by uniformprocessing and repli-
cate merging; peaks were defined by an FDR threshold of
1%. UCSC Genes was available from the UCSC Genome
Browser.17 Three histone marks (H3K4Me1, H3K4Me3, and
H3K27Ac) and transcription factor binding sites were based
on regions identified by chromatin immunoprecipitation
followed by sequencing. The ‘‘peaks’’ data available from
the UCSC Genome Browser17 were used: regions of sta-Table 1. Overrepresentation of ASM SNPs in the Functional Regions o
Functional Characteristic
SNPs with GW
ASM SNPs
Splice-site variants 0.0021
Nonsynonymous variants 0.0030
DNase hypersensitive clusters 0.4122
GTEx Consortium eQTLs 0.02850
UK Brain Consortium eQTLs 0.1268
UCSC Genes 0.5070
H3K4Me1 0.6508
H3K4Me3 0.4785
H3K27ac 0.6159
Transcription factor ChIP 0.2344
miRNA targets predicted by TargetScan 0
GENCODE transcription start sites 0.0936
ASM SNPs in the SCZ GWAS p% 0.1 bin were found in numerous functional regio
from hypergeometric test). In order to retain all group-specific ASM SNPs, we inv
SNPs and 122,186 non-ASM SNPs in the SCZ GWAS p% 0.1 bin. All SNPs were a
characteristic was indicated for the SNP itself. The following abbreviation is used:
960 The American Journal of Human Genetics 98, 956–962, May 5, 2tistically significant signal enrichment, where the score
associated with each enriched interval is the mean signal
value across the interval. miRNA targets were identified by
TargetScan.24 Transcription start sites were single base pairs
defined by GENCODE.25 For all of these annotations, we
considered available functional data regardless of cell type,
whereapplicable.Weperformedfunctionalgenomiccharac-
terization of ASM SNPs by using the hypergeometric test to
compare the frequencies of functional elements within
ASMSNPs to the oneswithin SNPs that didnot exhibit ASM.
A higher proportion of ASM SNPs than of non-ASM SNPs
in the SCZ GWAS p % 0.1 bin was detected at the locif the Genome
AS p % 0.1
p ValueNon-ASM SNPs
0.0009 0.0249
0.0039 0.7032
0.1483 2.02 3 10205
0.0109 4.51 3 1012
0.0885 3.80 3 1010
0.4207 3.06 3 1017
0.4392 3.00 3 1093
0.2419 7.22 3 10134
0.3931 1.27 3 10103
0.0821 4.54 3 10109
0 NA
0.0835 0.0396
ns of the genome more than expected by chance alone (uncorrected p values
estigated the union of the four lists of brain ASM SNPs. There were 2,351 ASM
nnotated in a binary fashion, such that the presence or absence of a functional
NA, not applicable.
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exhibiting epigenetic marks of enhancers (H3K4Me1: 0.65
versus 0.44, p ¼ 3 3 1093; H3K27ac: 0.61 versus 0.39,
p ¼ 1 3 10103) and promoters (H3K4Me3: 0.48 versus
0.24, p ¼ 73 10134), as well as within transcription factor
binding sites (0.23 versus 0.08, p ¼ 4.5 3 10109) and
DNase I hypersensitive sites (0.41 versus 0.15, p ¼ 2 3
10205) (Table 1). It is important to note, however, that
these epigeneticmarks investigated were not brain specific.
Well-characterized brain genomic functional data, which
are being generated through the PsychENCODE proj-
ect,26 will be particularly useful in GWASs of brain ASM.
Two recent articles also explored the additive value of
ASM in SCZ GWASs and arrived at conclusions very similar
to ours.27,28 Hannon et al. analyzed ASM (which they called
mQTLs [methylation quantitative trait loci]) in a fetal-brain
collection and detected significant enrichment of SCZ
GWAS significant SNPs among fetal-brain mQTLs. Jaffe
et al. showed that about half of the significant or sub-
threshold (p < 104) SNPs (or other SNPs in the LD block)
in a SCZGWASexhibitedmQTLeffects in theprefrontal cor-
tex. Because the two studies used a different platform (Illu-
mina HumanMethylation450 microarray) and different
design, direct comparison with our ASM findings is not
straightforward; however, the converging results of the
three studies indicate that ASM effects are associated with
disease risk.
In summary, we detected that brain ASM SNPs show
enrichment in GWAS sub-threshold SNP bins and exhibit
a gradient of the effect size: the smaller the p value of
sub-threshold SNPs, the larger the proportion of ASM
SNPs. If ASM was not associated with disease-risk SNPs,
the distribution of ASM SNPs across different GWAS
p value bins did not deviate from the one expected by
chance only. Furthermore, enrichment of brain ASM
SNPs was stronger in the SCZ GWAS than in the non-brain
phenotypes, and germline ASM SNPs exhibited enrich-
ment in the SCZ GWAS sub-threshold SNP bins, suggesting
a causal association between at least some ASM SNPs
and disease. Finally, SCZ ASM SNPs were overrepresented
in the functional regions of the genome, such as promoters
and enhancers. It can be hypothesized that epigenetic
differences at regulatory elements are central to the etiopa-
thogenic effects of SNPs, and this mechanism accounts for
differential regulation of disease-associated genes. The key
element of this model is that both DNA sequence and
epigenetic variation are necessary, and their synergistic
effects at the gene regulatory regions generate a bona
fide disease risk factor. Further ASM studies would
benefit from high-precision DNA-modification mapping
using bisulfite sequencing and differentiation among
cytosine methylation, hydroxymethylation, and other
modifications.Accession Numbers
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